What to expect from rational drug design

Expert Opinion on Drug Discovery

Volumn 2, Issue 6, 2007, Pages 773-776

  Adam, Matthias ^a  

^a BIELEFELD UNIVERSITY   (Germany)

Author keywords

Fragment based screening; Isolation paradigm; Structure guided drug design; Systems biology

Indexed keywords

BETA ADRENERGIC RECEPTOR; CAPTOPRIL; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; DIPEPTIDYL CARBOXYPEPTIDASE; EZETIMIBE; NITISINONE; PROPRANOLOL; PROTEINASE INHIBITOR; SEROTONIN 4 RECEPTOR; SIALIDASE INHIBITOR; TEGASEROD;

ANGINA PECTORIS; ARTICLE; CHEMICAL BOND; COMPUTER MODEL; DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; FOOD AND DRUG ADMINISTRATION; HIGH THROUGHPUT SCREENING; HUMAN; MATHEMATICAL MODEL; METHODOLOGY; MOLECULAR RECOGNITION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREDICTION; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTEIN TARGETING; RECEPTOR BLOCKING; STRUCTURE ACTIVITY RELATION; SYSTEMS BIOLOGY; X RAY CRYSTALLOGRAPHY;

EID: 34548087668     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2.6.773     Document Type: Article

References (17)

1. SCHWARDT O, KOLB H, ERNST B: Drug discovery today. Curr Top. Med. Chem. (2003) 3: 1-9.
2. CONGREVE M, MURRAY CW, BLUNDELL TL: Structural biology and drug discovery. Drug Discov. Today (2005) 10(13):895-907.
3. KUBINYI H: Drug research: myths, hype and reality. Nat. Rev. Drug Discov. (2003) 2(8):665-668.
4. BUTCHER EC: Can cell systems biology rescue drug discovery? Nat. Rev. Drug Discov. (2005) 4(6):461-467.
5. ERLANSON DA: Fragment-based lead discovery: a chemical update. Curr. Opin. Biotechnol. (2006) 17:643-652.
6. KITANO H: A robustness-based approach to systems-oriented drug design. Nat. Rev. Drug Discov. (2007) 6(3):202-210.
7. VAN DER GREEF J, MCBURNEY RN: Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat. Rev. Drug Discov. (2005) 4(12):961-967.
8. BLACK J: Drugs from emasculated hormones: the principle of syntopic antagonism. Science (1989) 245(4 August):486-493.
9. GAMBARDELLA A: Science and Innovation: The US Pharmaceutical Industry during the 1980s. Cambridge University Press, Cambridge (1995).
10. CUSHMAN D, ONDETTI M: History of the design of specific inhibitors of angiotensin converting enzyme. Hypertension (1991) 17(4):589-592.
11. NIGTHINGALE P, MARTIN P: The myth of the biotech revolution. Trends Biotechnol. (2004) 22(11):564-569.
12. HARDY LW, MALIKAYIL A: The impact of structure-guided drug design on clinical agents. Curr. Drug Discov. (2003) 3:15-20.
13. KUHN P, WILSON K, PATCH MG, STEVENS RC: The genesis of high-throughput structure-based drug discovery using protein crystallography. Curr. Opin. Chem. Biol. (2002) 6(5):704-710.
14. LOCK E, ELLIS MK, GASKIN P et al.: From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug. J Inher. Metab. Dis. (1998) 21:498-506.
15. ROSENBLUM SB, HUYNH T, AFONSO A et al.: Discovery of 1-(4-fluorphenyl)-(3R)-[3-(4-fluorphenyl)-(3S)-hydroxypropyl]-4S- (4-hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, orally active inhibitor of cholesterol absorption. J. Med. Chem. (1998) 41:973-980.
16. BUCHHEIT K, GAMSE R, GIGER R et al.: The serotonin 5-HT4 receptor 1. Design of a new class of agonists and receptor map of the agonist recognition site. J. Med. Chem. (1995) 38:2326-2330.
17. KOPPITZ M, EIS K: Automated medicinal chemistry. Drug Discov. Today (2006) 11 (11/12):561-568.